Zeo ScientifiX Q1 FY2026 revenue up 124.6% to $2.58M; net loss narrows to ~$1.0M

Zeo ScientifiX, Inc.

Revenue for quarter ended Apr 30, 2026: $2.58M vs $1.15M a year ago, +124.6%.
Six-month revenue: $4.03M vs $2.24M, +79.9%, driven by allogenic biologic products.
Gross margins maintained at ~80% for both six-month periods.
Net loss for six months reduced to ~$1.0M from ~$2.6M in prior-year period.
CEO cites growing physician adoption and commercial momentum in Florida.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.